Место инновационного препарата ранолазина в лечении ишемической болезни сердца
https://doi.org/10.21518/2079-701X-2014-12-44-48
Аннотация
Список литературы
1. Национальные рекомендации по диагностике и лечению стабильной стенокардии. Кардиоваскулярная терапия и профилактика, 2008, 6 (прил. 4): 1-40.
2. Berger P. Ranolazine and other antianginal therapies in era of the drug-eluting stent.JAMA, 2004, 291 (3): 365-367.
3. Bassand J-P. Clinical implications of inhibitor of the late sodium current: ranolazine. Eur Heart J, 2006, 8 (Suppl. A): A14-A19.
4. Aslam S., Gray D. Ranolazine (Renexa) in the treatment of chronic stable angina. Advances in Therapy, 2010, 27 (4): 193-201.
5. Patel P.D., Arora R.R. Utility of ranolazine in chronic stable angina patients. Cardiovasc Health Risk Manag, 2008, 4 (4): 819-824.
6. Lopaschuk GD, Kantor PF, Dyck JRB. Optimizing cardiac metabolism: a new reference approach in the management of ischemic heart disease? Medicographia, 1999, 21 (2):109-115.
7. Anderson JR, Nawarskas JJ. Ranolazine. A metabolic modulator for the treatment of chronic stable angina. Cardiol Rev, 2005, 13; 202-210.
8. Rousseau MF, Pouleur H, Cocco G, Wolff AF. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. AmJ Cardiol, 2005, 95: 311-316.
9. Chaitman BR, Skettino SL, Parker JO et al. for the MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol, 2004, 43: 1375-1382.
10. Stone PH, Gratsiansky NA, Blokhin A et al. for the ERICA investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol, 2006, 48: 566-575.
11. Chaitman BR, Pepine CJ, Parker JO et al. Combination Assessment of Ranolazine in Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.JAMA, 2004, 291: 309-316.
12. Timmis AD, et al. Eur Heart J, 2006, 27: 42-8.
13. Wilson SR, Scirica BM, Braunwald E ct al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) Trial. J Am Coll Cardiol, 2009, 53 (17): 1510-1516.
14. Morrow DA, Scirica BM, Chaitman BR et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation, 2009, Apr. 21, 119: 2032-2039.
15. Koren MJ et al. J Am Coll Cardiol, 2007, 49: 1027-34.
16. Jerling M, Huan BL, Leung K et al. Studies to investigate the pharmacokinetic interaction between ranolazine and ketoconazole, diltiazem or simvastatin during combined administration in healthy subjects. J Clin Pharmacol, 2005, 45: 422-433.
17. Keating G.M. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs, 2008, 68 (17): 2483-2503.
Рецензия
Для цитирования:
Барышникова Г.А., Чорбинская С.А., Степанова И.И. Место инновационного препарата ранолазина в лечении ишемической болезни сердца. Медицинский Совет. 2014;(12):44-48. https://doi.org/10.21518/2079-701X-2014-12-44-48
For citation:
Baryshnikova G., Chorbinskaya S., Stepanova I. Place of the novel drug ranolazine in the treatment of coronary artery disease. Meditsinskiy sovet = Medical Council. 2014;(12):44-48. (In Russ.) https://doi.org/10.21518/2079-701X-2014-12-44-48